Shares of two foreign drugmakers rose Monday after the companies secured approval from the Food and Drug Administration for their new medications, one a treatment for a rare genetic disorder and another for a common lung disease. Britain's Shire ( SHPGY) said Elaprase would reach the U.S. market in 30 days for a genetic disease that results in organ damage and early death. Shire's stock jumped $2.07, or 4.7%, to $46.43. AstraZeneca ( AZN) was also climbing after the Anglo-Swedish drug giant announced Saturday that the FDA had approved its asthma drug Symbicort. Though already sold in more than 90 countries, Symbicort won't reach the U.S. until mid-2007. AstraZeneca's stock rose $1.79, or 3%, to $61.37. Shire's Elaprase treats a disease called Hunter syndrome. Shire says Elaprase is the first treatment for the disease, which is caused by the absence of or inadequate levels of a certain enzyme. Elaprase must be given in weekly infusions. The U.S. accounts for 25% of the market, and Shire estimates there are 2,000 Hunter syndrome patients worldwide in markets where reimbursement may be possible. Shire submitted an application to the European Union in December, and it expects a decision by year-end. AstraZeneca's Symbicort was approved by the FDA as a twice-daily treatment. The product combines two drugs, budesonide and formoterol, in one inhaler. The drug is prescribed as maintenance therapy for patients 12 years and older. The federal Centers for Disease Control says an estimated 20 million Americans have asthma, according to the latest data compiled in 2002. The CDC says asthma affects 6.1 million children under the age of 18.